Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lilly, Boehringer Partner In Diabetes
by Ann M. Thayer
January 17, 2011
| A version of this story appeared in
Volume 89, Issue 3
Eli Lilly & Co. and Boehringer Ingelheim will jointly develop a portfolio of diabetes compounds that are in or nearing late-stage development. Lilly will pay $390 million up front to Boehringer Ingelheim, which could also receive up to $820 million in milestone payments related to two oral diabetes agents it will contribute to the alliance. For its two insulin analogs, Lilly could gain $650 million in milestones. If Boehringer chooses to develop Lilly’s anti-TGF-β monoclonal antibody, Lilly would be eligible for up to $525 million more in potential payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter